Pipeline Regulation

Sac-TMT and sonesitatug vedotin hit Phase 3 gastric survival while missing central PFS

Merck and Kelun-Biotech's (HKEX: 06990) TROP2 ADC sac-TMT (TroFuse-015, NCT06356311) and AstraZeneca/Keymed's (02162.HK) CLDN18.2 ADC sonesitatug vedotin (NCT06346392) both hit Phase 3 OS while missing BICR-PFS.

Sac-TMT and sonesitatug vedotin hit Phase 3 gastric survival while missing central PFS
China Pharma Desk cross-comparison of Phase 3 gastroesophageal ADC trials TroFuse-015 (NCT06356311) and CLARITY-Gastric01 (NCT06346392) alongside Chinese CLDN18.2 and EGFRxHER3 ADC competitors.

Within 24 hours on November 19 and November 20, 2026, two Chinese-originated antibody-drug conjugates (ADCs) advanced at the top of the global late-line gastroesophageal cancer landscape—and exposed the exact same statistical split between overall survival (OS) and blinded central progression-free survival (BICR-PFS). On November 20, Merck (NYSE: MRK) and Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 06990) announced that the global Phase 3 TroFuse-015 trial (NCT06356311, n=473) of TROP2-directed ADC sacituzumab tirumotecan (sac-TMT / MK-2870 / SKB264) met its primary endpoint of OS in third-line or later (3L+) locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (GEA), while missing its secondary endpoint of BICR-PFS. One day earlier, AstraZeneca (LSE/NASDAQ: AZN) and originators Keymed Biosciences (HKEX: 02162) and Lepu Biopharma (HKEX: 02157) disclosed that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review (target PDUFA action date in Q2 2027) to the Biologics License Application (BLA) for Claudin 18.2 (CLDN18.2)-directed ADC sonesitatug vedotin (Sone-Ve / AZD0901 / CMG901) based on the global Phase 3 CLARITY-Gastric01 trial (NCT06346392, n=594)—a study that doubled 3L+ median OS from 5.0 to 10.0 months (HR 0.47, p<0.000001) and improved intention-to-treat (ITT) 2L+ OS to 10.6 versus 6.4 months (HR 0.58, p=0.000004), yet narrowly missed its co-primary ITT BICR-PFS endpoint (4.2 versus 3.8 months, HR 0.77, p=0.053193).

For global oncology investors and regulatory teams, the twin announcements carry two immediate implications. First, five Chinese-originated ADCs—spanning TROP2, CLDN18.2, and EGFR×HER3—now anchor the late-stage global and domestic registration pipeline for pretreated gastric and gastroesophageal junction (GEJ) cancer. Second, in direct contrast to Akeso (HKEX: 09926) and Summit Therapeutics’ (NASDAQ: SMMT) ivonescimab FDA Complete Response Letter two weeks ago—where a PFS benefit without statistically significant OS failed U.S. review—the FDA’s grant of Priority Review to sonesitatug vedotin confirms that robust OS separation overrides a central PFS miss in refractory upper gastrointestinal tumors, even as subgroup hazard ratios (2L OS HR 0.88 versus 3L+ OS HR 0.47) set up a critical Q2 2027 U.S. label-scope test.

Six Chinese-originated and global gastroesophageal ADCs compared

While Astellas Pharma’s (TSE: 4503) naked monoclonal antibody zolbetuximab (Vyloy) established CLDN18.2 in first-line HER2-negative gastric cancer (requiring  ≥ 75% moderate-to-strong 2+/3+ membranous staining), ADCs have fractured the pretreated gastroesophageal market across three distinct axes: target biomarker cutoffs (all-comer TROP2 versus CLDN18.2 >= 25% at any intensity versus CLDN18.2 >= 75% at 2+/3+), cytotoxic payload classes (topoisomerase I inhibitors versus microtubule inhibitor MMAE), and commercial rights structures (full global out-licensing, ex-Greater China splits, or domestic pharma buyouts):

Asset & Codes Originator / Global Partner & Deal Structure Target & Biomarker Cutoff Linker & Payload (DAR) Pivotal Trial & Line (NCT ID) Primary Endpoint Readout (OS vs. PFS) Regulatory Status (as of Nov 21, 2026)
sacituzumab tirumotecan (sac-TMT / MK-2870 / SKB264) Kelun-Biotech (06990.HK) / Merck (NYSE: MRK, ex-Greater China exclusive license) TROP2 (All-comer); central tissue testing for stratification, no cutoff exclusion Pyrimidine-sulfone hydrolyzable linker + belotecan-derivative Topo-I (KL610023, DAR ~7.4) TroFuse-015 (NCT06356311, n=473), global 3L+ GEA (4 mg/kg Days 1, 15, 29 Q6W vs. TPC) Primary OS: Met across all TROP2 subgroups; Secondary BICR-PFS: Missed; nominal ORR improvement Global regulatory filings planned (Nov 20, 2026); China 3L+ Phase 3 OptiTROP-Gastric01 (NCT06023797) ongoing
sonesitatug vedotin (Sone-Ve / AZD0901 / CMG901) Keymed (02162.HK, 70% KYM) & Lepu (02157.HK, 30% KYM) / AstraZeneca (AZN, $63m upfront + $45m Ph3 milestone + up to $1.1b total, global incl. China) CLDN18.2 >= 25% of tumor cells at any intensity (~60% of GC/GEJ population) Protease-cleavable linker + MMAE microtubule payload (DAR ~4) CLARITY-Gastric01 (NCT06346392, n=594, 19 countries), global 2L+ GEC (2.2 mg/kg Q3W n=267 vs. ICT n=265) Co-primary 3L+ OS: Met (10.0 vs. 5.0 mo, HR 0.47, p<0.000001); Key secondary ITT OS: Met (10.6 vs. 6.4 mo, HR 0.58); Co-primary ITT BICR-PFS: Missed (4.2 vs. 3.8 mo, p=0.0532) U.S. FDA BLA Priority Review (Nov 19, 2026; PDUFA Q2 2027); China NMPA (CDE) NDA accepted (Oct 8, 2026); EU under review
arcotatug tavatecan (IBI343 / TAK-921) Innovent Biologics (01801.HK) / Takeda (TSE: 4502 / NYSE: TAK, Oct 2025 $1.2b upfront / $11.4b package for ex-Greater China rights) CLDN18.2 >= 75% of tumor cells at 2+/3+ membranous intensity Cleavable linker + exatecan Topo-I payload (DAR ~4) with Fc-silenced antibody G-HOPE-001 (NCT06238843), multi-regional 3L+ GC/GEJ vs. investigator’s choice Co-primary PFS: Met at June 2026 interim analysis; co-primary OS maturing China NMPA NDA accepted under Priority Review (June 2026); global filings pending mature OS
vetecotatug vedotin (LM-302 / TPX-4589) LaNova Medicines / Sino Biopharmaceutical (01177.HK, acquired via ~$500m net buyout of LaNova in July 2025) CLDN18.2 positive (>= 25% at 2+/3+ in 1L Phase 3 combination) Cleavable valine-citrulline linker + MMAE payload (DAR ~4) China Phase 3 (NCT05934331), 3L+ GC/GEJ; plus 1L Phase 3 + PD-1 (dosed Apr 2026) Interim dual endpoints: Met (June 2026 announcement; numerical effect sizes slated for early 2027 congress) China NMPA NDA accepted under Priority Review (June 23, 2026); U.S. FDA Orphan Drug Designation
SHR-A1904 Jiangsu Hengrui (600276.SS / 01276.HK) (wholly owned) CLDN18.2 positive (Phase 1 Nature Medicine Sept 2025) Cleavable linker + proprietary Topo-I payload China Phase 3 (NCT06649292, estimated n=524), 2L GC/GEJ vs. paclitaxel/docetaxel/irinotecan Single primary endpoint: OS (recruiting; primary completion target Sept 20, 2027) China CDE Breakthrough Therapy Designation (BTD, Dec 26, 2025)
iza-bren (BL-B01D1 / izalontamab brengitecan) Sichuan Biokin / SystImmune (688506.SS) / BMS (NYSE: BMY, $800m upfront + $500m milestones paid) EGFR×HER3 bispecific (broad epithelial expression in HER2-negative GC/GEJ) Cleavable linker + Ed-04 camptothecin Topo-I payload (DAR ~8) China Phase 3 (NCT06496516, 2L+ GC/GEJ) & Phase 2 1L HER2- GC/GEJ + sintilimab Phase 2 1L HER2- GC/GEJ + sintilimab poster at ESMO Asia (Dec 4, 2026, 17:15 SGT, Prof. He Wei) Phase 3 recruiting in 2L+ GC/GEJ; approved/filed in NSCLC and NPC

Why both Phase 3 trials hit OS while missing central PFS

In solid-tumor oncology, drugs far more commonly achieve progression-free survival (PFS) while failing to demonstrate overall survival (OS) after post-progression crossover. Seeing two independent global Phase 3 trials—one with a TROP2 Topo-I ADC (TroFuse-015) and one with a CLDN18.2 MMAE ADC (CLARITY-Gastric01)—deliver the exact opposite outcome (OS positive, BICR-PFS negative) points to three structural features of heavily pretreated gastroesophageal carcinoma:

  1. Rapid first-scan progression compresses median PFS separation: In 3L+ gastric and GEJ adenocarcinoma, standard single-agent chemotherapy comparators (trifluridine/tipiracil [Lonsurf], irinotecan, paclitaxel, docetaxel, or China-specific apatinib) typically progress at or near the first scheduled radiographic assessment at Week 6 to Week 12. In CLARITY-Gastric01, median BICR-PFS in the ITT population was 4.2 months (95% CI, 3.5–5.3) on sonesitatug vedotin versus 3.8 months (95% CI, 3.0–4.2) on comparator therapy (HR 0.77, p=0.053193). When nearly half of patients progress around the second restaging scan, the median PFS point estimate barely moves, whereas the hazard ratio and survival tail capture durable responders—driving a doubling of 12-month OS in 3L+ patients from 18.1% to 38.1% (median OS 10.0 vs. 5.0 months, HR 0.47).
  2. High central-versus-local radiographic discordance in peritoneal and gastric wall disease: Advanced gastric cancer frequently metastasizes to the peritoneum, omentum, and retroperitoneal lymph nodes, accompanied by non-measurable malignant ascites and diffuse primary gastric wall thickening. Blinded central radiologists (BICR) reading scans without clinical context frequently call early equivocal fluid changes or non-target lesion shifts differently from treating physicians. In CLARITY-Gastric01, while ITT BICR-PFS missed statistical significance (4.2 vs. 3.8 months, HR 0.77), investigator-assessed PFS in the exact same ITT population showed a clear 4.4 versus 3.0 month separation (HR 0.59, 95% CI, 0.48–0.73), and 3L+ BICR-PFS separated at 4.1 versus 2.7 months (HR 0.56, 95% CI, 0.43–0.74, though not formally tested under the multiplicity hierarchy).
  3. Different trial endpoint hierarchies determined headline success: Merck designed TroFuse-015 (n=473) exclusively in 3L+ GEA with OS as the sole primary endpoint and BICR-PFS relegated to a secondary endpoint—insulating sac-TMT from central radiographic noise. Similarly, Jiangsu Hengrui’s ongoing 524-patient Phase 3 trial of SHR-A1904 in 2L CLDN18.2-positive GC/GEJ (NCT06649292) uses OS as its single primary endpoint. By contrast, AstraZeneca designed CLARITY-Gastric01 (n=594) across a combined 2L+ population with dual primary endpoints (3L+ OS and ITT 2L+ BICR-PFS), winning the trial on the 3L+ OS alpha split while missing the ITT BICR-PFS gate.

The Q2 2027 FDA label question for sonesitatug vedotin: 2L+ or 3L+?

Although AstraZeneca’s BLA was accepted under Priority Review for the broad 2L+ CLDN18.2 >= 25% population, the subgroup forest plot presented by Professor Xu Ruihua at the 2026 ESMO Presidential Symposium highlights a sharp regulatory question for the FDA’s Oncology Center of Excellence (OCE) ahead of the Q2 2027 PDUFA date:

  • Biomarker cutoff breadth is well-supported: Across expression strata in CLARITY-Gastric01, patients with high expression (CLDN18.2 >= 75%) achieved a median OS of 10.6 versus 6.4 months (HR 0.59, 95% CI, 0.45–0.78), while those in the lower 25% to <75% bracket achieved 10.5 versus 6.2 months (HR 0.63, 95% CI, 0.42–0.94). That consistency validates sonesitatug vedotin’s MMAE bystander effect and supports its lower  ≥ 25% threshold (covering ~60% of gastric tumors) over the stricter  ≥ 75% at 2+/3+ cutoff used by Innovent and Takeda’s arcotatug tavatecan (IBI343) in G-HOPE-001.
  • Line-of-therapy and anatomic site heterogeneity is much wider: While 3L+ patients (n=178 vs. 177, ~67% of the 2.2 mg/kg cohort) delivered an overwhelming OS benefit (10.0 versus 5.0 months, HR 0.47), the unadjusted OS hazard ratio among 2L patients was HR 0.88 (95% CI, 0.60–1.30)—where active comparator regimens included ramucirumab + paclitaxel—and HR 1.08 (95% CI, 0.68–1.71) in the gastroesophageal junction and esophageal adenocarcinoma (GEJ/EAC) subset.

For sac-TMT (MK-2870), Merck avoided the 2L ramucirumab + paclitaxel comparator hurdle in TroFuse-015 by restricting enrollment to 3L+ patients—and gained an all-comer survival readout that requires no companion diagnostic cutoff at all (OS benefit consistent regardless of TROP2 expression). For Kelun-Biotech (06990.HK), which completed its generational chairmanship transition to Liu Sichuan on November 18, TroFuse-015 represents the second positive global Phase 3 readout under Merck’s 18-trial global TroFuse program, expanding sac-TMT beyond lung, breast, and gynecologic malignancies into upper gastrointestinal oncology.

What to watch next

  1. December 4, 2026 (ESMO Asia, Singapore): SystImmune and Sichuan Biokin (688506.SS) will present seven abstracts across iza-bren (BL-B01D1, including the 1L HER2-negative GC/GEJ + sintilimab Phase 2 poster at 17:15 SGT) and HER2 ADC T-Bren (BL-M07D1, oral presentations in colorectal and urothelial cancers on December 4 and 6).
  2. Early 2027 gastrointestinal oncology congress (ASCO GI): Expected full numerical presentation of TroFuse-015 (median OS, hazard ratio, Grade  ≥ 3 stomatitis and hematologic toxicity rates, and TROP2-high vs. TROP2-low subgroup curves) alongside Sino Biopharm’s (01177.HK) Phase 3 readout for vetecotatug vedotin (LM-302).
  3. Q2 2027 U.S. FDA PDUFA decision for sonesitatug vedotin (AZD0901): Whether the FDA grants AstraZeneca the full 2L+ CLDN18.2 >= 25% gastric/GEJ/EAC indication or narrows the U.S. label to 3L+ gastric adenocarcinoma, and whether any approval milestone is triggered for Keymed (70% of KYM) and Lepu Biopharma (30% of KYM).